Viridian Therapeutics, Inc.
NASDAQ:VRDN
19.03 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.314 | 1.772 | 2.963 | 1.05 | 4.461 | 8.386 | 4.003 | 3.337 | 2.538 | 4.32 | 4.316 | 4.406 |
| Cost of Revenue
| 1.322 | 0.755 | 0.62 | 28.304 | 32.794 | 30.421 | 19.623 | 2.548 | 2.472 | 3.243 | 2.499 | 3.042 |
| Gross Profit
| -1.008 | 1.017 | 2.343 | -27.254 | -28.333 | -22.035 | -15.62 | 0.789 | 0.066 | 1.077 | 1.818 | 1.364 |
| Gross Profit Ratio
| -3.21 | 0.574 | 0.791 | -25.956 | -6.351 | -2.628 | -3.902 | 0.236 | 0.026 | 0.249 | 0.421 | 0.31 |
| Reseach & Development Expenses
| 159.765 | 100.894 | 56.886 | 28.304 | 34.794 | 30.421 | 19.623 | 0.888 | 1.002 | 0.293 | 0.097 | 0.225 |
| General & Administrative Expenses
| 94.999 | 35.182 | 25.805 | 13.265 | 11.646 | 11.049 | 10.912 | 7.906 | 7.692 | 7.034 | 1.788 | 2.908 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.669 | 2.559 | 0.717 | 0.379 | 1.325 |
| SG&A
| 94.999 | 35.182 | 25.805 | 13.265 | 11.646 | 11.049 | 10.912 | 9.575 | 10.251 | 7.751 | 2.167 | 4.233 |
| Other Expenses
| 0 | 0 | 0 | 69.861 | 0 | 0 | 0 | 2.834 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 254.764 | 136.076 | 82.691 | 41.569 | 46.44 | 41.47 | 30.535 | 10.463 | 11.253 | 8.044 | 2.264 | 4.459 |
| Operating Income
| -254.45 | -134.304 | -79.728 | -110.38 | -41.979 | -33.084 | -26.532 | -12.508 | -11.187 | -6.867 | -0.196 | -4.027 |
| Operating Income Ratio
| -810.35 | -75.792 | -26.908 | -105.124 | -9.41 | -3.945 | -6.628 | -3.748 | -4.408 | -1.59 | -0.045 | -0.914 |
| Total Other Income Expenses Net
| 16.716 | 4.43 | 0.315 | -0.335 | 0.106 | 0.381 | 0.02 | -0.166 | -0.141 | -1.023 | -1.713 | -1.591 |
| Income Before Tax
| -237.734 | -129.874 | -79.413 | -110.715 | -41.873 | -32.703 | -26.512 | -12.674 | -11.328 | -7.89 | -2.16 | -5.618 |
| Income Before Tax Ratio
| -757.115 | -73.292 | -26.802 | -105.443 | -9.386 | -3.9 | -6.623 | -3.798 | -4.463 | -1.826 | -0.5 | -1.275 |
| Income Tax Expense
| 0 | -4.43 | 0.003 | 0.269 | 0.547 | 1.254 | 0.095 | 0.095 | 0 | 1.023 | 1.963 | 3.184 |
| Net Income
| -237.734 | -125.444 | -79.416 | -110.984 | -42.42 | -32.703 | -26.512 | -12.674 | -11.328 | -7.89 | -2.16 | -7.211 |
| Net Income Ratio
| -757.115 | -70.792 | -26.803 | -105.699 | -9.509 | -3.9 | -6.623 | -3.798 | -4.463 | -1.826 | -0.5 | -1.637 |
| EPS
| -5.31 | -3.91 | -6.66 | -31.2 | -20.31 | -16.57 | -20.66 | -17.57 | -21 | -52.46 | -11.48 | -38.75 |
| EPS Diluted
| -5.31 | -3.91 | -6.66 | -31.2 | -20.31 | -16.57 | -20.66 | -17.57 | -21 | -52.46 | -11.48 | -38.75 |
| EBITDA
| -234.565 | -128.633 | -78.79 | -109.668 | -40.75 | -31.549 | -25.821 | -12.508 | -11.003 | -6.723 | -0.048 | -3.883 |
| EBITDA Ratio
| -747.022 | -73.018 | -26.76 | -38.425 | -9.199 | -3.796 | -6.527 | -2.842 | -4.335 | -1.579 | -0.069 | -0.67 |